Compare Fabrinet (FN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs GeneDx Holdings Corp — how do they compare? Fabrinet trades at $488.12 (market cap $17.46B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Fabrinet is far larger — about 8.6× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 1,199,886). Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 30 Days and GeneDx Holdings Corp for 19 Days on average.
| FN | WGS | |
|---|---|---|
Market Cap | $17.46B | $2.02B |
Volume | 1,199,886 | 734,640 |
Sector | Technology | Health |
52-Week High | $746.47 | $167.51 |
52-Week Low | $361.94 | $34.51 |
Typical Hold Time | 30 Days | 19 Days |
Enterprise Value | $16.59B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $493.25, down 0.95% amid mixed technical signals with bullish moving averages but overbought RSI readings. The company demonstrates strong fundamental performance with 45% Q4 revenue growth and consistent earnings beats, driven by surging AI data center demand. Analyst consensus remains strongly bullish with a $769.50 price target representing 56% upside potential, though the stock faces near-term pressure from high capital expenditures.
Fabrinet's AI infrastructure positioning and capacity expansion support long-term growth prospects, but investors should monitor customer concentration risks and margin pressures. The stock's premium valuation (P/E 37.34) requires continued execution on growth targets to justify current levels amid competitive optical component market dynamics.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
